Recent advances in antitumor vaccines.
Immunization with anti-idiotypic antibodies can induce cell-mediated and humoral antitumor immunity in animal models. This immunity can sometimes cause tumor destruction. However, more needs to be learned about how best to induce the type of immune response that is responsible for tumor destruction, since the presence of anti-idiotypic antibodies has been shown occasionally to enhance, rather than to inhibit, tumor growth. There is evidence suggesting that immunization of human cancer patients with Ab2 can have therapeutic benefit, and also that patients who mount a vigorous Ab2 response following treatment with an Ab1 may do clinically better than those who do not make any Ab2. Although the generation of Ab2 related to infused antitumor Ab1 does not cause tumor rejection in the majority of patients, and although the clinical data from patients given Ab2 are scarce, the suggestion that Ab2 may cause destruction of human cancers indicates that further work in this area may become rewarding.
Hu
S L
SL
Hellström
I
I
Hellström
K E
KE
D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000627:therapeutic use; D000943:Antigens, Differentiation / Q000276:immunology / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control*; D027383:Papillomaviridae / Q000276:immunology; D014612:Vaccines / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D000956:Antigens, Viral; D014612:Vaccines